论文部分内容阅读
目的评价莫西沙星与左氧氟沙星治疗泌尿道感染的疗效、不良反应及成本-效果。方法采用随机、开放、平行对照试验设计。选择泌尿道感染病例195例,其中可评价病例176例,莫西沙星组(治疗组)90例,给予莫西沙星400 mg,1次/d,疗程7~14 d;左氧氟沙星组(对照组)86例,给予左氧氟沙星200 mg,2次/d,疗程为10 d。结果莫西沙星组临床总有效率97.8%,左氧氟沙星组91.9%,两组的细菌清除率分别为96.7%和94.2%,不良反应发生率分别为7.78%和9.30%,两组比较差异均无统计学意义(P>0.05),成本效果比分别为2.67和0.51(P<0.01)。结论左氧氟沙星的治疗方案为治疗泌尿道感染的较佳方案。
Objective To evaluate the efficacy, adverse effects and cost-effectiveness of moxifloxacin and levofloxacin in the treatment of urinary tract infections. Methods Randomized, open, parallel controlled trial design. 195 cases of urinary tract infection were selected, of which 176 cases were evaluable, 90 cases were treated with moxifloxacin (treatment group), 400 cases were given moxifloxacin once daily for 7-14 days, while those in levofloxacin group (control group) 86 cases were given levofloxacin 200 mg twice daily for 10 days. Results The total effective rate was 97.8% in the moxifloxacin group and 91.9% in the levofloxacin group. The bacterial clearance rates in the two groups were 96.7% and 94.2% respectively, and the incidences of adverse reactions were 7.78% and 9.30% respectively, with no statistical difference between the two groups Significance (P> 0.05), cost-effectiveness ratio was 2.67 and 0.51 (P <0.01). Conclusion Levofloxacin treatment is a better treatment of urinary tract infections.